0.5993

15.76% -0.1121

After Hours: .62 0.0207 +3.45%

Prokidney Corp (PROK)

Overview News Price History Option Chain Financials Discussions Forecast

Prokidney Corp stock is traded at $0.5993, with a volume of 4.88M. It is down -15.76% in the last 24 hours and down -41.82% over the past month. ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Previous Close:

$0.7114

Open:

$0.6942

24h Volume:

4.88M

Relative Volume:

9.45

Market Cap:

$77.63M

Revenue:

Net Income/Loss:

$-35.47M

P/E Ratio:

-1.0514

EPS:

-0.57

Net Cash Flow:

$-124.27M

1W Performance:

-34.14%

1M Performance:

-41.82%

6M Performance:

-64.64%

1Y Performance:

-58.38%

1-Day Range:

$0.55

$0.70

1-Week Range:

$0.55

$1.00

52-Week Range:

$0.55

$4.44

Prokidney Corp Stock (PROK) Company Profile

Name

Prokidney Corp

Sector

Healthcare (1171)

Industry

Biotechnology (673)

Phone

336-999-7028

Address

2000 FRONTIS PLAZA BLVD., WINSTON-SALEM

Employee

204

Twitter

Next Earnings Date

2024-12-09

Latest SEC Filings

PROK's Discussions on Twitter

Compare PROK with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PROK Prokidney Corp	0.5993	77.63M	0	-35.47M	-124.27M	-0.57
VRTX Vertex Pharmaceuticals Inc	474.62	121.88B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	573.45	62.69B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	555.11	33.86B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	235.74	30.51B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	238.51	25.69B	3.81B	-644.79M	-669.77M	-6.24

Prokidney Corp Stock (PROK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-30-24	Initiated	JP Morgan	Neutral
Sep-10-24	Initiated	Guggenheim	Buy
Mar-07-24	Resumed	Morgan Stanley	Equal-Weight
Jan-02-24	Downgrade	BofA Securities	Buy → Neutral
Jul-25-23	Initiated	BTIG Research	Buy
Dec-21-22	Initiated	Jefferies	Buy
Nov-10-22	Initiated	Morgan Stanley	Equal-Weight
Oct-18-22	Initiated	UBS	Buy
Oct-14-22	Initiated	Citigroup	Buy
Sep-23-22	Initiated	BofA Securities	Buy
Sep-02-22	Initiated	Evercore ISI	Outperform

View All

Prokidney Corp Stock (PROK) Latest News

Mar 29, 2025

Bank of New York Mellon Corp Has $388,000 Holdings in ProKidney Corp. (NASDAQ:PROK) - Defense World

Mar 29, 2025

Mar 27, 2025

Here's Why We're Watching ProKidney's (NASDAQ:PROK) Cash Burn Situation - Yahoo Finance

Mar 27, 2025

Mar 21, 2025

Down -38% in 4 Weeks, Here's Why You Should You Buy the Dip in PROKIDNEY CP (PROK) - Yahoo Finance

Mar 21, 2025

Mar 20, 2025

PROK stock touches 52-week low at $0.94 amid market challenges - Investing.com India

Mar 20, 2025

ProKidney Corp reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 20, 2025

Mar 18, 2025

ProKidney Hold Rating: Balancing Developmental Progress and Financial Stability Amid Uncertainty - TipRanks

Mar 18, 2025